

Curriculum Vitae (Brief edition), 09/2019

Kalliopi Zachou MD, PhD

Associate Professor in Medicine, University of Thessaly

Department of Medicine and Research Laboratory of Internal Medicine, University Hospital of Larissa, Larissa, Greece.

Personal Data

Date of birth May 25, 1969
Birthplace Larissa
Marital status Married, mother of two children
Home address 12 M. Katraki str, Larissa
Business address Department of Medicine and Research Lab of Internal
Medicine, University Hospital of Larissa, Larissa,
Greece.
Current position Associate Professor in Medicine
Business phone 0030 2413502889
e-mail zachoukalliopi@gmail.com
Languages Greek (native language), English (Proficiency,
Cambridge Univ., U.K.), French (Certificat 1er degré,
Univ. de Sorbonne)

Education - Professional experience

12/1993 Degree in Medicine, Aristotelian University of
Thessaloniki
04/1994 – 10/1995 GP in Health Center of Gonni, Larissa (obligatory service
according to Greek law)
10/1995 – 02/1998 Resident, Dept of Internal Medicine, 1st General Hospital
of Thessaloniki, 'Saint Paul'.
03/1998 – 03/1999 Postgraduate student in a one year course on
Emergency Medicine of the National Institution of
Emergency Services
11/1999 – 11/2002 Senior House officer, Division of Internal Medicine,

General Hospital of Larissa (Director: Mr K. Karamitsios) and Research Associate, laboratory of Internal Medicine, Larissa Medical School, University of Thessaly (Director: Prof. N. Stathakis)

- 01/2003** Title of Speciality in Internal Medicine
- 07/2003** Ph.D in Medicine (doctoral thesis entitled: “Prevalence of liver-kidney microsomal antibodies (anti-LKM) and other non-organ specific autoantibodies in patients with hepatitis C”)
- 01/2003 – 2005** Attending Physician in Academic Liver Unit and Post-doc Fellow in the Research Laboratory of Internal Medicine, Medical School, University of Thessaly.
- 08/2005 – 08/2006** Post doctoral fellowship at the University of Hannover, Medical School, Dept of Gastroenterology, Hepatology and Endocrinology (Director: Prof. Dr. M.P. Manns).
- 05/2011 – today** Chief of the Research Laboratory of Internal Medicine, University of Thessaly (Director: Prof. GN Dalekos).
- 08/2006 – 02/2013** Consultant in the Department of Medicine and the Academic Liver Unit and Research Laboratory of Internal Medicine University Hospital of Larissa, Greece (Director: 2006-2008 Prof. Dr N. Stathakis, 2008-today Prof. Dr G.N. Dalekos).
- 07/ 2010** Election as an Assistant Prof. of Medicine, Larissa Medical School, Faculty of Health Sciences, University of Thessaly.
- 02/2013 – today** Assistant Professor of Medicine, Larissa Medical School, Faculty of Health Sciences, University of Thessaly.
- 4/2019** Election as an Associate Prof. of Medicine, Larissa Medical School, Faculty of Health Sciences, University of Thessaly.
- 08/2019-today** Associate Professor of Medicine, Larissa Medical School, Faculty of Health Sciences, University of Thessaly.

Research experience (in brief)

1999-2003: postgraduate student in the Department of Medicine and Research Lab of Internal Medicine, University of Thessaly, Larissa Medical School, being one of the funding members of the Lab of Internal Medicine. During this time I gained experience in immunological techniques and *in-house* methods such as indirect immunofluorescence on fresh rat liver-kidney-stomach cryostat sections, enzyme linked immunosorbent assays, western blotting on cytosolic, mitochondrial and microsomal extracts and PCR technics.

2003-2005: postdoctoral researcher in the Department of Medicine and Research Lab of Internal Medicine, University of Thessaly, Larissa Medical School

2005-2006: postdoctoral researcher in the Medizinische Hochschule Hannover, Dept of Gastroenterology and Hepatology, Director: Prof. Dr. M.P. Manns where I was trained on further immunological techniques such as cell cultures, flow cytometry, ELISPOT, immunohistochemistry as well as real time PCR and sequencing.

2006-today: I am Scientific Supervisor of the immunological and virological Department of the Research Lab of Internal Medicine, University of Thessaly, Larissa Medical School, where multiple sophisticated techniques used are established in our laboratory (*in-house* methods like indirect immunofluorescence on fresh rat liver-kidney-stomach cryostat sections, western blotting on cytosolic, mitochondrial and microsomal extracts, etc.). These tests are not performed anywhere in Greece in a similarly standardized way. The Laboratory has been acknowledged as a reference center for the diagnostic approach of autoantibodies detection in autoimmune liver diseases and therefore, a considerable number of sera of undiagnosed patients from major tertiary hospitals of the country but also from private hospitals/ health institutions and private practitioners are investigated annually. As a result, the Department of Medicine and Research Laboratory of Internal Medicine has been recorded by the Hellenic Center for Disease Control & Prevention as a Special Rare Diseases Center for Autoimmune Hepatitis. In addition, detection and quantification of the viral load of hepatitis B, C D and E viruses is performed in the Laboratory with modern standardized molecular techniques (HCV-RNA, HBV-DNA with real-time PCR technique, HCV genotyping and quantification of HDV-RNA and HEV-RNA). Several studies are performed in the Laboratory focusing on various scientific fields either in biological specimens of patients like the immunopathogenesis of autoimmune hepatitis, primary biliary cirrhosis and viral hepatitis B, C, D, and E.

My research interests target the study of the pathogenesis as well as the epidemiology, natural history, diagnosis, clinical expression, therapy of liver diseases in total with special emphasis on autoimmune liver diseases.

License to practice Medicine: 21250/13-12-1993

Member of Societies/ committees

- Hellenic Association for the Study of the Liver
- European Association for the Study of the Liver
- Society of Internal Medicine of North Greece
- Hellenic Professional Association of Internal Medicine
- Hepatitis Delta International network
- Global PBC International Study Group
- International PSC Study Group
- International Autoimmune Hepatitis Study Group
- Member of the working group of the Hellenic Association for the Study of the Liver for the composition of the Greek guidelines for Autoimmune Hepatitis (on line, 6-4-2015).

Postgraduate courses: participation in 42 postgraduate courses

72 invited Lectures. Representative Lectures:

1. Medizinische Hochschule Hannover, 18 Ιουλίου 2006. Einladung zum Werkstattgesprach of Abteilung Gastroenterologie und Hepatologie. Thema: **“Significance of quantitative HBsAg and HDVRNA levels in Delta hepatitis”**.
2. 11th Panhellenic Hepatology Congress, Corfu, May 7-10, 2009. Lecture entitled: **“Steatosis and autoimmune liver diseases”**.
3. 8th Educational conference of the Hellenic Foundation of Gastroenterology and Nutrition entitled “Developments in Gastroenterology and Hepatology”, Athens, February 8-9, 2013. Lecture entitled: **“Developments in autoimmune liver diseases”**.

4. Postgraduate course organized by the Department of Medicine and Research Lab of Internal Medicine, University of Thessaly, Larissa, October 30, 2014. Lecture entitled: **“Primary biliary cirrhosis: Diagnosis – natural history – treatment”**.
5. 14th Panhellenic Hepatology Congress, Kos Island, May 7-10, 2015. Lecture entitled: **“Autoimmune hepatitis”**.
6. 25th United European Gastroenterology Week, Barcelona Spain, October 28-November 1, 2017. **“From guidelines to clinical practice: Autoimmune hepatitis”**.

Awards

1. 2nd Award in the 8th Hellenic Symposium on Hepatitis C entitled: *«Anticardiolipin antibodies (a-CLAbs) are not b2-GPI-dependent (non-thrombogenic a-CLAbs): preliminary results in 107 HCV patients from central Greece»* presented in Athens, January 27, 2001.
2. 1st Award in poster session by the Hellenic Association for the Study of the Liver entitled: *«Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis»* presented in the 8th Panhellenic Congress of Hepatology, Thessaloniki, May 8-11, 2003.
3. Selection after crisis from the EASL Scientific Committee among the 30 out of 90 candidates to attend the EASL School of Hepatology Course 1 – Chronic Liver Diseases, Geneva, Switzerland (5-7 December 2003).
4. Selection after crisis from the EASL Scientific Committee among the 30 out of 90 candidates to attend the EASL School of Hepatology Course 3 – Liver transplantation, The Liver immunity and autoimmune diseases, Birmingham (UK) (3-4 December 2004).
5. One year scholarship (2005-2006) from the Scientific committee and the Administrative Council of the Hellenic Association for the Study of the Liver as a Post doctoral fellow at the University of Hannover, Medical School, Dept of Gastroenterology, Hepatology and Endocrinology (Director: Prof. Dr. M.P. Manns).
6. Award for best oral presentation in the 10th Congress of the European Federation of Internal Medicine, entitled *«Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of patients»* presented in Athens, 5-8 October, 2011.

7. 2nd Award by the Hellenic Association for the Study of the Liver entitled: *“Decreased production of hepcidin in patients with autoimmune liver diseases”* presented in the 13th Panhellenic Congress of Hepatology, Rhodes, May 9-12, 2013.
8. 1st Award for the Best Poster Presentation in the 11th Panhellenic Congress of Clinical Chemistry for the study entitled: *“Non interventional investigation of liver diseases by using caffeine test detection in urine”* presented in Volos, October 11-12, 2013.
9. 1st Award of Oral Presentation in the 1st Panhellenic Congress of Continuing Education in Internal Medicine for the study entitled: *“Long-term outcome of patients with autoimmune hepatitis (AIH) receiving Mycophenolate Mofetil (MMF) as first line treatment”* presented in Thessaloniki, February 26-28, 2015.
10. 3rd Award of Best Oral Presentation in the 14th Panhellenic Congress of the Hellenic Association for the Study of the Liver for the study entitled: *“Decrease serum DNase-1 activity in patients with autoimmune liver diseases”* presented in Kos Island, May 7-10, 2015.
11. 2nd Award of Best Poster Presentation in the 14th Panhellenic Congress of the Hellenic Association for the Study of the Liver for the study entitled: *“Treatment of portal thrombosis in cirrhotic patients”* presented in Kos Island, May 7-10, 2015.
12. 1st Award of Best oral Presentation in the 15th Panhellenic Congress of the Hellenic Association for the Study of the Liver, Larissa, May 25-27, 2017, entitled: *“Significance of IP10 in patients with HBeAg negative chronic hepatitis B, after withdrawal of long term treatment with entecavir (ETV) or tenofovir (TDF): prospective study DARING-B”*.
13. 1st Award of Best oral Presentation in the 37th Panhellenic Congress of Gastroenterology, Thessaloniki, October 5-7, 2017, entitled: *“Direct acting antivirals (DAA) in the therapy of chronic hepatitis C (CHC) in current clinical practice. HERACLIS: Hellenic multicenter prospective study”*.
14. 1st Award of Best oral Presentation in the 16th Panhellenic Congress of the Hellenic Association for the Study of the Liver, Athens, May 4-6, 2018, entitled: *“Metabolic profil of patients with autoimmune hepatitis at diagnosis and after disease remission with 1H NMR”*.
15. Best research abstract award, in the 18th European Congress of Internal Medicine, Lisbon, Portugal, August 29-31, 2019 entitled: *“The diverse face of*

Familial Mediterranean Fever (FMF) In Greece: the importance of R202Q mutation of Mediterranean Fever (MEFV) Gene”.

Other activities

1. **Supervisor of 3 PhD students** and member of the **evaluating committee of 7 PhD thesis** which have been completed successfully.
2. **Supervisor of 2 Msc thesis** which have been completed successfully.
3. **Regular reviewer** for the journals: Alimentary Pharmacology & Therapeutics, African Journal of Microbiology Research, Annals of Gastroenterology, Annals of Hepatology, Annual Review & Research in Biology, Autoimmune Diseases, BMC Infectious Diseases, BMJ Gastroenterology, British Journal of Medicine and Medical Research, Case Reports in Hepatology, Clinical and Experimental Medicine, Clinics Research in Hepatology and Gastroenterology, Digestive and Liver Diseases, European Journal of Gastroenterology & Hepatology, Expert Opinion On Drug Safety, Expert Review of Clinical Immunology, Gastroenterology & Hepatology International Journal, Genes, Hepatitis Monthly, Hippocratia, Infection, International Journal of Molecular Science, International Urology and Nephrology, Journal of Gastroenterology & Hepatology Research, Journal of Clinical Pharmacy and Therapeutics, Journal of Gastroenterology Hepatology Research, Journal of Hepatology Reports, Journal of Laboratory Medicine, Journal of Viral Hepatitis, Mathews Journal of Gastroenterology & Hepatology, Medical Science
4. **Member of the Editorial Board (invited)** of International Journal of Autoimmune Disorders & Therapy (2015), Mathews Journal of Gastroenterology & Hepatology (2016), Gastroenterology & Hepatology International Journal (2017), Annals of Gastroenterology (Section Editor, Liver) (2017).
5. **Founding member** of the Research Laboratory of Internal Medicine, University of Thessaly Medical School (foundation date:11/98).
6. **Chief** of the one out of three groups of specialty registrars of the Department of Medicine and Research Lab of Internal Medicine of the University of Thessaly (09/2008 - today).
7. **Member of the Working Group** of the Society of Internal Medicine of Southern Greece for Liver diseases (2011 – today).
8. **Member of Hepatitis Delta International Network** (a group dedicated to the study of the hepatitis delta virus since 2007).

9. **Member of the Global PBC International Study Group** (2014).
10. **Member of the Council of the Medical School**, University of Thessaly (09/2013 – 09/2014 and 09/2015-09/2016).
11. **Founding member** of the Institute of Internal Medicine and Hepatology (2012 – today)
12. **Vice president** of the Transplantation Committee of the University Hospital of Larissa (2012 – today).
13. **Reviewer** on behalf of the United European Gastroenterology (UEG) Week Vienna, October 18-22, 2014 and October 15-19, 2015.
14. **Reviewer** on behalf of the 7th International Congress of Internal Medicine of Central Greece, 19-21 March, 2015.
15. **Member** of the panel of the Hellenic (Greek) Clinical Practice **Guidelines of Autoimmune Hepatitis** published by the Hellenic Association for the Study of the Liver (April 2015).
16. **Collaboration** with Professor D. Vergani (King's College London) and Professor J. Rodes (Barcelona, Spain) on the prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis published in *Gut*.
17. **Sub-investigator** in the study entitled: "A multicenter randomized study comparing the efficacy of adefovir dipivoxil vs. pegylated interferon-alfa-2a plus placebo vs. adefovir dipivoxil plus pegylated interferon-alfa-2a for the treatment of chronic delta hepatitis", published in *Liver International, New England Journal of Medicine, Antiviral Therapy, Journal of Viral Hepatitis & Turkish Journal of Gastroenterology*.
18. **Collaboration** with Prof. M.P. Manns (Hannover, Germany) and Prof. H. Tillmann (Leipzig, Germany) on the safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience, which is published in *Journal of Viral Hepatitis*.
19. **Sub- investigator** in the "Phase 3b, Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients with Lamivudine-Resistant Chronic Hepatitis B Who Have Limited Treatment Options (GS-01-550)", which has been completed in March 2004.
20. **Sub- investigator** in a multicenter, double blinded study in patients with chronic hepatitis C who are non-responders to prior peginterferon-a or peginterferon-a + ribavirin therapy comparing treatment with thymosin a1 + peginterferon-a-2a plus

ribavirin with peginterferon-a-2a + ribavirin + placebo (2005-2008, Co-ordinator: Professor M. Rizzetto).

21. **Sub- investigator** in a multicenter, double blinded study on Tenofovir vs Adefovir in the treatment of naïve patients with chronic anti-HBe positive hepatitis B (2006-now; we have been audited for this study by American authorities funded by Gilead with excellent conclusions).

22. **Collaboration** with Prof. M.P. Manns (Hannover, Germany) and Prof. H. Wedemeyer (Hannover, Germany) on the cross-genotype reactivity of the immunodominant HCV-CD8 T-cell epitope NS3-1073 which is published in *Vaccine*.

23. **Sub-investigator** in 40 clinical trials.

I recieved ICH Good Clinical Practice E6 (R2), certificate number 650050, score 89%, 02/05/2019

I have attended in 83 Greek and International Congresses (1994-2019) and I have presented 216 abstracts

BIBLIOGRAPHY

A. Thesis

Doctoral Thesis: "Incidence of liver-kidney microsomal antibodies (anti-LKM) and of other non-organ specific autoantibodies in patients with chronic hepatitis C". Larissa 2003.

B. Publications in International medical journals [impact factors (IF) 2018, JCR Science Edition]

1. Dalekos GN, **Zachou K**, Liaskos C. The antiphospholipid syndrome and infection (**invited review**). *Curr Rheumatol Rep* 2001, 3(4):277-85. **IF: 3.079**
2. Christodoulou DK, Dalekos GN, Merkouropoulos M, Kistis KG, Georgitsi G, Zervou E, **Zachou K**, Tsianos EV. Cryoglobulinemia due to chronic viral hepatitis infections is not a major problem in clinical practice. *Eur J Intern Med* 2001; 12:435-441. **IF: 3.282**

3. Dalekos GN, **Zachou K**, Liaskos C, Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. *Eur J Intern Med* 2002; 13:293-303. **IF: 3.282**
4. Dalekos GN, Makri E, Loges S, Obermayer-Straub P, **Zachou K**, Tsirikas Th, Schmidt E, Papadamou G, Manns MP. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. *Eur J Gastroenterol Hepatol* 2002; 14:35-42. **IF: 2.014**
5. **Zachou K**, Liaskos C, Christodoulou DK, Kardasi M, Papadamou G, Gatselis N, Georgiadou SP, Tsianos EV, Dalekos GN. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. *Eur J Clin Invest* 2003; 33: 161-168. **IF: 3.086**
6. Kyriakou DS, Alexandrakis MG, **Zachou K**, Passam F, Stathakis NE, Dalekos GN. Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. *J Hepatol* 2003; 39:679-685. **IF: 15.04**
7. **Zachou K**, Rigopoulou E, Liaskos C, Patsiaoura K, Makri E, Stathakis N, Dalekos GN. Primary biliary cirrhosis presented as peripheral eosinophilia in asymptomatic women with or without elevated alkaline phosphatase. *Eur J Gastroenterol Hepatol* 2004;16(4):425-8. **IF: 2.014**
8. Georgiadou SP, **Zachou K**, Rigopoulou E, Liaskos C, Mina P, Gerovasilis F, Makri E, Dalekos GN. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases. *J Viral Hepat* 2004; 11(4):358-65. **IF: 4.237**
9. **Zachou K**, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. *J Autoimmune Dis* 2004; 1:2. **IF: - (Invited Review; this article has qualified as 'Highly accessed'; Accesses 41.690 up to 31-12-2017; see <http://www.jautoimdis.com/content/4/1/2/about>).**
10. Gatselis NK, Georgiadou SP, Tassopoulos N, **Zachou K**, Liaskos C, Hatzakis A, Dalekos GN. Impact of parietal cell autoantibodies and non-organ-specific

- autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study. *World J Gastroenterol* 2005; 28;11(4):482-7. **IF: 3.3**
11. Tsikrikoni A, Kyriakou DS, Rigopoulou EI, Alexandrakis MG, **Zachou K**, Passam F, Dalekos GN. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. *J Hepatol* 2005; 42(3):393-9. **IF: 15.04**
 12. Rigopoulou EI, Davis ET, Pares A, **Zachou K**, Liaskos C, Bogdanos D-P, Dalekos GN, Vergani D. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. *Gut* 2005; 54:528-532. **IF: 17.016**
 13. Liaskos C, Rigopoulou EI, **Zachou K**, Georgiadou SP, Gatselis N, Papamihali R, Dalekos GN. Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. *J Autoimmun* 2005; 24:251-260. **IF: 7.607**
 14. **Zachou K**, Rigopoulou EI, Tsikrikoni A, Alexandrakis MG, Passam F, Kyriakou DS, Stathakis NE and Dalekos GN. Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. *J Autoimmun* 2005; 25:283-288. **IF: 7.607**
 15. Rigopoulou EI, Stefanidis I, Liaskos C, Zervou EK, Rizos C, Mina P, **Zachou K**, Syrganis C, Patsidis E, Kyriakopoulos G, Sdrakas L, Tsianas N, Dalekos GN. HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: results from five hemodialysis units in central Greece. *J Clin Virol* 2005; 34:81-85. **IF: 3.101**
 16. Germanis AE, Yiannaki EE, **Zachou K**, Roka V, Barbanis S, Liaskos C, Adam K, Kapsoritakis AN, Potamianos S, Dalekos GN. Prevalence and clinical significance of immunoglobulin A antibodies against tissue transglutaminase in patients with diverse chronic liver diseases. *Clin Diagn Lab Immunol* 2005; 12:941-948. **IF: 2.51**
 17. Nikaina I, Pastaka C, **Zachou K**, Dalekos GN, Gourgouljanis K. Sleep apnoea syndrome and early stage cirrhosis: a pilot study. *Eur J Gastroenterol Hepatol* 2006; 18:31-35. **IF: 2.014**

18. **Zachou K**, Liaskos C, Rigopoulou EI, Gabeta S, Papamichalis P, Gatselis N, Georgiadou S, Dalekos GN. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. *Clin Immunol* 2006;119:203-12. **IF: 3.557**
19. Zografos Th, Rigopoulou EI, Liaskos C, Togousidis E, **Zachou K**, Gatselis N, Germanis A, Dalekos GN. Alterations of leptin during IFN- α therapy in patients with chronic viral hepatitis. *J Hepatol* 2006; 44:848-55. **IF: 15.04**
20. Tillmann HL, Hadem J, Leifeld L, **Zachou K**, Canbay A, Eisenbach C, Graziadei I, Encke J, Schmidt H, Vogel W, Schneider A, Spengler U, Gerken G, Dalekos GN, Wedemeyer H, Manns MP. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. *J Viral Hepat* 2006; 13:256-63. **IF: 4.237**
21. Guéguen P, Dalekos GN, Nousbaum J-B, **Zachou K**, Putterman C, Youinou P, Renaudineau Y. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. *J Clin Immunol* 2006; 26:495-505. **IF: 4.227**
22. Gatselis NK, Georgiadou SP, Koukoulis GK, Tassopoulos N, **Zachou K**, Liaskos C, Hatzakis A, Dalekos GN. Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. *Aliment Pharmacol Ther* 2006; 24:1563-73. **IF: 7.357**
23. Papamichalis PA, **Zachou K**, Koukoulis GK, Veloni A, Karacosta EG, Kypri L, Mamaloudis I, Gabeta S, Rigopoulou EI, Lohse AW, Dalekos GN. The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. *J Autoimmune Dis* 2007; 4:3. **IF: -**
(This article has qualified as 'Highly accessed'; Accesses up to 31-12-2017: 29.449; see <http://www.jautoimdis.com/content/4/1/3/about>)
24. Renaudineau Y, Dalekos GN, Guéguen P, **Zachou K**, Youinou P. Anti- α -actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. *Clin Rev Allergy Immunol* 2008; 34:321–325. **IF: 6.442**

25. Tsirikoni A, Rigopoulou EI, **Zachou K**, Liaskos C, Kyriakou D, Dalekos GN. Bone marrow findings in patients with autoimmune liver diseases. *J Gastroenterol Hepatol* 2008; 23 e416–e421. **IF: 3.483**
26. **Zachou K**, Papamichalis PA, Dalekos GN. Severe pharyngitis in stockbreeders: an unusual presentation of brucellosis. *Occup Med (Lond)* 2008; 58:305-307. **IF: 1.482**
27. Gabeta S, Norman GL, Gatselis N, Liaskos C, Papamichalis PA, Garagounis A, **Zachou K**, Rigopoulou EI, Dalekos GN. IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. *J Clin Immunol* 2008; 28:501-11. **IF: 4.227**
28. Fytilli P, Dalekos GN, Schlaphoff V, Suneetha PV, Sarrazin C, Zauner W, **Zachou K**, Berg T, Manns MP, Klade CS, Cornberg M, Wedemeyer H. Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. *Vaccine* 2008; 26:3818-3826. **IF: 3.285**
29. Stefanidis I, Giannopoulou M, Liakopoulos V, Dovas S, Karasavvidou F, **Zachou K**, Koukoulis GK, Dalekos GN. A case of membranous nephropathy associated with Sjögren syndrome, polymyositis and autoimmune hepatitis. *Clin Nephrol* 2008; 70:245-50. **IF: 1.352**
30. Georgiadou SP, **Zachou K**, Liaskos C, Gabeta S, Rigopoulou EI, Dalekos GN. Occult hepatitis B virus infection in patients with autoimmune liver diseases. *Liver Int* 2009; 29:434-42. **IF: 4.5**
31. Stefos A, Gatselis N, **Zachou K**, Rigopoulou E, Hadjichristodoulou C, Dalekos GN. Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. *Eur J Intern Med* 2009; 20:35-43. **IF: 3.079**
32. Tsironi E, Gatselis N, Kotoula MG, **Zachou K**, Pefkianaki M, Zacharaki F, Chatzoulis DZ, Dalekos GN. Ocular disorders as the prevailing manifestations of antiphospholipid syndrome: a case series. *Cases J* 2009; 20:159. **IF: -**
33. **Zachou K**, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Bozkaya H, Schlaphoff V, Dienes HP, Bock TC, Manns MP, Wedemeyer H; for H1DT-1 Study Group. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. *Liver Int* 2010; 30(3):430-7. **IF: 4.5**

34. Gatselis NK, **Zachou K**, Papamichalis P, Koukoulis GK, Gabeta S, Dalekos GN, Rigopoulou EI. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: A new or a complementary diagnostic score? *Dig Liver Dis* 2010; 42:807-12. **IF: 3.287**
35. Gatselis NK, **Zachou K**, Dalekos GN, Rigopoulou EI. Early primary biliary cirrhosis: a new association with erythema nodosum of unknown origin. *Gastroenterol Res Pract* 2010;2010. pii: 121620. **IF: 1.859**
36. Wedemeyer H, Yurdaydın C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H, Gürel S, Zeuzem S, **Zachou K**, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP; HIDIT Study Group. Pegylated interferon alfa-2a plus adefovir dipivoxil versus either drug alone for hepatitis delta. *N Engl J Med* 2011; 364:322-31. **IF: 79.258**
37. **Zachou K**, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of patients. *J Hepatol.* 2011; 55:636-46. **IF: 15.04**
38. Oikonomou KG, **Zachou K**, Dalekos GN. Alpha-actinin: A multidisciplinary protein with important role in B-cell driven autoimmunity. *Autoimmun Rev.* 2011; 10:389-96. **IF: 8.745**
39. **Zachou K**, Dalekos GN. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. *Liver Int.* 2011; 31:277-9 (Editorial). **IF: 4.5**
40. Koumati E, Palassopoulou M, Matsouka P, Polyzos A, Dalekos GN, **Zachou K**. Multiple autoimmune propensity and B-non-Hodgkin lymphoma: cause or effect? *Autoimmune Dis.* 2011;2011:841325. **IF:-**
41. Grabowski J, Yurdaydın C, **Zachou K**, Buggisch P, Hofmann WP, Jaroszewicz J, Schlaphoff V, Manns MP, Cornberg M, Wedemeyer H; the HIDIT-1 study group. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. *Liver Int.* 2011; 31:1395-405. **IF: 4.5**
42. **Zachou K**, Oikonomou K, Renaudineau Y, Chauveau A, Gatselis N, Youinou P, Dalekos GN. Anti- α actinin antibodies as new predictors of response to treatment

- in autoimmune hepatitis type 1. *Aliment Pharmacol Ther.* 2012; 35:116-25. **IF: 7.357**
43. Argyraki CK, Gabeta S, **Zachou K**, Boulbou M, Polyzos A, Dalekos GN. Favourable outcome of life-threatening infectious-related haemophagocytic syndrome after combination treatment with corticosteroids and intravenous immunoglobulin infusions. *Eur J Intern Med* 2011; 22(6):e155-7 (Letter). **IF: 3.282**
44. Tillmann HL, **Zachou K**, Dalekos GN. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? *Liver Int.* 2012; 32:544-53. **IF: 4.5**
45. Gatselis NK, **Zachou K**, Norman GL, Tzellas G, Speletas M, Gabeta S, Germenis A, Koukoulis GK, Dalekos GN. IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. *Clin Chim Acta* 2012; 413:1683-1688. **IF: 2.926**
46. Heidrich B, Serrano BC, Idilman R, Kabaçam G, Bremer B, Raupach R, Önder FO, Deterding K, Zacher BJ, Taranta A, Bozkaya H, **Zachou K**, Tillmann HL, Bozdayi AM, Manns MP, Yurdaydin C, Wedemeyer H. HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. *Liver Int.* 2012;32:1415-25. **IF: 4.5**
47. Zografos TA, Gatselis N, **Zachou K**, Liaskos C, Gabeta S, Koukoulis GK, Dalekos GN. PBC-specific autoantibodies in first degree relatives of Greek PBC patients. *World J Gastroenterol* 2012; 18:4721-4728. **IF: 3.3**
48. Kabaçam G, Dalekos GN, Cakaloğlu Y, **Zachou K**, Bock T, Erhardt A, Zeuzem S, Tabak F, Yalçın K, Bozdayi AM, Dienes HP, Bozkaya H, Manns M, Wedemeyer H, Yurdaydin C. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. *Turk J Gastroenterol* 2012; 23:560-568. **IF: 0.869**
49. Mederacke I, Yurdaydin C, Großhennig A, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, **Zachou K**, Chatzikyrkou C, Bozkaya H, Dalekos GN, Manns MP, Wedemeyer H; on behalf of Hep-Net/International Delta Hepatitis Study Group. Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. *J Viral Hepat* 2012; 19:387-395. **IF: 4.237**

50. Mederacke I, Yurdaydin C, Dalekos GN, Bremer B, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, **Zachou K**, Bozkaya H, Dienes HP, Manns MP, Wedemeyer H; Hep-Net/International Delta Hepatitis Study Group. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon- α 2a treatment. *Antivir Ther* 2012;17:305-12. **IF: 2.146**
51. Skrimpas S, Polyzos A, Dalekos GN, **Zachou K**. Quiz: Sternoclavicular joint swelling in a previously healthy adult. *Internal Med: Open Access* 2:2, 2012. **IF: 0.536**
52. A Mazioti, NK Gatselis, C Rountas, **K Zachou**, DK Filippiadis, K Tepetes, GK Koukoulis, I Fezoulidis, GN Dalekos. Safety and efficacy of transcatheter arterial chemoembolization in the real-life management of unresectable hepatocellular carcinoma. *Hepat Mon* 13:e7070, 2013. **IF: 1.81**
53. Saitis A, Gatselis N, **Zachou K**, Dalekos GN. Use of TNFa antagonists in refractory AIH: revealing the unforeseen. *J Hepatol (Letter)* 2013; 59:197-198. **IF: 15.04**
54. Gatselis NK, **Zachou K**, Norman GL, Gabeta S, Papamichalis P, Koukoulis GK, Dalekos GN. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. *Autoimmunity* 2013; 46:471-479. **IF: 2.648**
55. **Zachou K**, Sarantopoulos A, Gatselis NK, Vassiliadis T, Gabeta S, Stefos A, Saitis A, Boura P, Dalekos GN. HBV reactivation in HBsAg negative patients receiving immunosuppression: a hidden threat. *World J Hepatol* 2013; 5:387-392. **IF:-**
56. **Zachou K**, Muratori P, Koukoulis GK, Granito A, Gatselis N, Fabbri A, Dalekos GN, Muratori L. Review article: Autoimmune hepatitis – its aetiopathogenesis, clinical features, diagnosis and management. *Aliment Pharmacol Ther* 2013; 38:887-913. **IF: 7.357**
57. Rigopoulou EI, **Zachou K**, Gatselis NK, Papadamou G, Koukoulis GK, Dalekos GN. Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. *World J Hepatol* 2013; 5:577-583. **IF: -**

58. Rigopoulou EI, **Zachou K**, Gatselis N, Koukoulis GK, Dalekos GN. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. *Ann Hepatol* 2014; 13:127-135. **IF: 1.576**
59. Heidrich B, Yurdaydin C, Kabaçam G, Ratsch BA, **Zachou K**, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalçın K, Gurel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H. Late HDV RNA relapse after peginterferon alfa-based therapy of chronic hepatitis delta. *Hepatology* 2014;60(1):87-97. **IF: 14.079**
60. Gatselis NK, **Zachou K**, Saitis A, Samara M, Dalekos GN. Individualization of chronic hepatitis C treatment according to the host characteristics. *World J Gastroenterol* 2014; 20(11):2839-2853. **(Invited Review) IF: 3.3**
61. **Zachou K**, Gampeta S, Gatselis NK, Oikonomou K, Goulis J, Manoussakis MN, Renaudineau Y, Bogdanos DP, Dalekos GN. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. *Liver Int* 2015; 35(2):660-72. **IF: 4.5**
62. Gatselis NK, **Zachou K**, Koukoulis GK, Dalekos GN. Autoimmune hepatitis, one disease with many faces: Etiopathogenetic, clinico-laboratory and histological characteristics. *World J Gastroenterol* 2015; 21(1):60-83. **(Invited Review) IF: 3.3**
63. Keskin O, Wedemeyer H, Tüzün A, **Zachou K**, Deda X, Dalekos GN, Heidrich B, Pehlivan S, Zeuzem S, Yalçın K, Gürel S, Tabak F, Idilman R, Bozkaya H, Manns M, Yurdaydin C. Association between level of Hepatitis D Virus RNA at week 24 of Pegylated Interferon therapy and outcome. *Clin Gastroenterol Hepatol* 2015;13(13):2342-2349. **IF: 7.683**
64. Kalafateli M, Kourakli A, Gatselis N, Lambropoulou P, Thomopoulos K, Tsamandas A, Christofidou M, **Zachou K**, Jelastopoulou E, Nikolopoulou V, Symeonidis A, Dalekos GN, Lambropoulou-Karatza C, Triantos C. Efficacy of Interferon A-2b monotherapy in B-thalassemics with chronic hepatitis C. *J Gastrointestin Liver Dis* 2015 Jun;24(2):189-96. **IF: 1.964**
65. Lyberopoulou A, Chachami G, Gatselis NK, Kyratzopoulou E, Saitis A, Gabeta S, Eliades P, Paraskeva E, **Zachou K**, Koukoulis GK, Mamalaki A, Dalekos GN, Simos G. Low Serum Hcpidin in Patients with Autoimmune Liver Diseases. *PLoS One* 2015;10(8):e0135486. **IF: 2.766**

66. **K. Zachou**, N. K. Gatselis, P. Arvaniti, S. Gabeta, E. I. Rigopoulou, G. K. Koukoulis, G. N. Dalekos. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. *Aliment Pharmacol Ther* 2016; 43:1035-1047 (**Original article with Editorial**). **IF: 7.357**
- Dalekos GN**, Zachou K. Editorial: autoimmune hepatitis - identifying options for treatment. Authors' reply. *Aliment Pharmacol Ther* 43:1237-1238, 2016.
67. Niro GA, Smedile A, Fontana R, Olivero A, Ciancio A, Valvano MR, Pittaluga F, Coppola N, Wedemeyer H, **Zachou K**, Marrone A, Fasano M, Lotti G, Andreone P, Iacobellis A, Andriulli A, Rizzetto M. HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response. *Aliment Pharmacol Ther* 2016;44:620-8. **IF: 7.357**
68. **Zachou K**, Gabeta S, Shums Z, Gatselis NK, Koukoulis GK, Norman GL, Dalekos GN. COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. *Eur J Intern Med* 2017;38:83-88. **IF: 3.282**
69. **Zachou K**, Arvaniti P, Gatselis NK, Azariadis K, Papadamou G, Rigopoulou E, Dalekos GN. Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016? *Mediterr J Hematol Infect Dis* 2017 1;9(1):e2017003. **IF: 1.183**
70. Gatselis NK, Vakrakou AG, **Zachou K**, Androutsakos T, Azariadis K, Hatzis G, Manoussakis MN, Dalekos GN. Decreased serum DNase1-activity in patients with autoimmune liver diseases. *Autoimmunity* 2017;50(2):125-132. **IF: 2.648**
71. Sinakos E, Kountouras D, Koskinas J, **Zachou K**, Karatapanis S, Triantos C, Vassiliadis T, Goulis I, Kourakli A, Vlachaki E, Toli B, Tampaki M, Arvaniti P, Tsiaoussis G, Bellou A, Kattamis A, Maragkos K, Petropoulou F, Dalekos GN, Akriviadis E, Papatheodoridis GV. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β -thalassaemia major and advanced liver disease. *Br J Haematol* 2017;178(1):130-136. **IF: 5.128**
72. **Zachou K**, Gabeta S, Gatselis NK, Norman GL, Dalekos GN. Cartilage oligomeric matrix protein on the spot for liver fibrosis evaluation: Too early or too late? *Eur J Intern Med* 2017;43:e48-e49 (Letter). **IF: 3.282**
73. Gatselis NK, **Zachou K**, Lygoura V, Azariadis K, Arvaniti P, Spyrou E, Papadamou G, Koukoulis GK, Dalekos GN, Rigopoulou EI. Geoepidemiology,

clinical manifestations and outcome of primary biliary cholangitis in Greece. *Eur J Intern Med.* 2017 Jul;42:81-88. **IF: 3.282**

74. Alberts R, de Vries EMG, Goode EC, Jiang X, Sampaziotis F, Rombouts K, Böttcher K, Folseraas T, Weismüller TJ, Mason AL, Wang W, Alexander G, Alvaro D, Bergquist A, Björkström NK, Beuers U, Björnsson E, Boberg KM, Bowlus CL, Bragazzi MC, Carbone M, Chazouillères O, Cheung A, Dalekos G, Eaton J, Eksteen B, Ellinghaus D, Färkkilä M, Festen EAM, Floreani A, Franceschet I, Gotthardt DN, Hirschfield GM, Hoek BV, Holm K, Hohenester S, Hov JR, Imhann F, Invernizzi P, Juran BD, Lenzen H, Lieb W, Liu JZ, Marschall HU, Marzioni M, Melum E, Milkiewicz P, Müller T, Pares A, Rupp C, Rust C, Sandford RN, Schramm C, Schreiber S, Schrupf E, Silverberg MS, Srivastava B, Sterneck M, Teufel A, Vallier L, Verheij J, Vila AV, Vries B, **Zachou K**; International PSC Study Group, The UK PSC Consortium, Chapman RW, Manns MP, Pinzani M, Rushbrook SM, Lazaridis KN, Franke A, Anderson CA, Karlsen TH, Ponsioen CY, Weersma RK. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. *Gut* 2018;67(8):1517-1524. **IF: 17.016**
75. Papatheodoridi M, Dalekos GN, Goulis J, Manolakopoulos S, Triantos C, **Zachou K**, Koukoufiki A, Kourikou A, Zisimopoulos K, Tsoulas C, Papatheodoridis GV. Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice. *Ann Gastroenterol* 2017;30(5):542-549. **IF: -**
76. Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, Dalekos GN, Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P, Vanwolleghem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C, Manns MP, Wedemeyer H, Hardtke S, Serrano B, Wöbse M, Heidrich B, Mucbe M, Gatselis N, **Zachou K**, Ho E, Smedile A, Fontana R, Gish R, Obretin D, Stern R. Hepatitis Delta International Network. Clinical and virological heterogeneity of hepatitis delta in different regions worldwide: The Hepatitis Delta International Network (HDIN). *Liver Int* 2018;38(5):842-850. **IF: 4.5**

77. Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, **Zachou K**, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. *Hepatology* 2018;67(5):1920-1930. **IF: 14.079**
78. Doumtsis P, Oikonomou T, Goulis I, **Zachou K**, Dalekos G, Cholongitas E. Type 1 autoimmune hepatitis presenting with severe autoimmune neutropenia. *Ann Gastroenterol* 2018;31(1):123-126. **IF: -**
79. Arvaniti P, **Zachou K**, Koukoulis GK, Dalekos GN. Postinfantile giant cell hepatitis with features of acute severe autoimmune hepatitis probably triggered by diclofenac in a patient with primary myelofibrosis. *Case Reports Hepatol* 2018 11;2018:9793868. **IF: -**
80. Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, **Zachou K**, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. *Antivir Ther* 2018;23(8):677-685. **IF: 2.146**
81. **Zachou K**, Arvaniti P, Azariadis K, Lygoura V, Gatselis NK, Lyberopoulou A, Koukoulis GK, Dalekos GN. Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. *Hepatol Res* 2019;49(1):96-104. **IF: 3.415**
82. Zachos I, **Zachou K**, Tzortzis V, Dalekos GN. Management of patients with liver cirrhosis and invasive bladder cancer: A case-series. *J Transl Int Med* 2019;7:29-33. **IF:-**
83. Charras A, Arvaniti P, Le Dantec C, Arleevskaya MI, **Zachou K**, Dalekos GN, Bordon A, Renaudineau Y. JAK Inhibitors Suppress Innate Epigenetic Reprogramming: a Promise for Patients with Sjögren's Syndrome. *Clin Rev Allergy Immunol* 2019 Jun 4. doi: 10.1007/s12016-019-08743-y. **IF: 7.328**

84. Dalekos GN, Gatselis NK, **Zachou K**. Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation? *Liver Transpl* 2019; 25(10):1588-1589. **IF: 4.159**
85. Gatselis NK, Goet JC, **Zachou K**, Lammers WJ, Janssen HLA, Hirschfield G, Corpechot C, Lindor KD, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Lygoura V, Nevens F, Mason AL, Kowdley KV, Ponsioen CY, Bruns T, Thorburn D, Verhelst X, Harms MH, van Buuren HR, Hansen BE, Dalekos GN; Global Primary Biliary Cholangitis Study Group. Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. *Clin Gastroenterol Hepatol* 2019 Aug 13. pii: S1542-3565(19)30888-2. doi: 10.1016/j.cgh.2019.08.013. [Epub ahead of print]. **IF: 7.958**
86. Papatheodoridi M, Hadziyannis E, Berby F, **Zachou K**, Testoni B, Rigopoulou E, Gatselis NK, Lyberopoulou A, Vlachogiannakos I, Manolakopoulos S, Dalekos GN, Zoulim F, Papatheodoridis GV. Predictors of HBsAg loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in non-cirrhotic HBeAg-negative chronic hepatitis B. *J Viral Hepat.* 2019 Sep 28. doi: 10.1111/jvh.13211. [Epub ahead of print]. **IF: 4.016**

Total IF= 475.998

Citation index

Citations till 2018 Google Scholar: 4908, Scopus: 2422, Self citations: 270

h index (Scopus): 28

h index (Google Scholar): 35

i10-index: 70